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Circulating microRNAs -192 and 
-194 are associated with the 
presence and incidence of diabetes 
mellitus
Andrea Jaeger1,2, Lukas Zollinger1,2, Christoph H. Saely3,4,5, Axel Muendlein3,4,5, 
Ioannis Evangelakos6, Dimitris Nasias6, Nikoleta Charizopoulou6, Jonathan D. Schofield7,8, 
Alaa Othman1,2, Handrean Soran7,8, Dimitris Kardassis6, Heinz Drexel3,4,5,9 & 
Arnold von Eckardstein1,2
We sought to identify circulating microRNAs as biomarkers of prevalent or incident diabetes. In a pilot 
study of 18 sex- and age-matched patients with metabolic syndrome, nine of whom developed diabetes 
during 6 years of follow-up, an array of 372 microRNAs discovered significantly elevated serum levels 
of microRNAs -122, -192, -194, and -215 in patients who developed diabetes mellitus type 2 (T2DM). In 
two cross-sectional validation studies, one encompassing sex- and age-matched groups of patients with 
T2DM, impaired fasting glucose (IFG) and euglycemic controls (n = 43 each) and the other 53 patients 
with type 1 diabetes and 54 age- and BMI-matched euglycemic controls, serum levels of miR-192, miR-
194, and mi215 were significantly higher in diabetic subjects than in probands with euglycemia or IFG. 
In a longitudinal study of 213 initially diabetes-free patients of whom 35 developed diabetes during 
6 years of follow-up, elevated serum levels of microRNAs 192 and 194 were associated with incident 
T2DM, independently of fasting glucose, HbA1c and other risk factors. Serum levels of miR-192 and 
miR-194 were also elevated in diabetic Akt2 knockout mice compared to wild type mice. In conclusion, 
circulating microRNAs -192 and -194 are potential biomarkers for risk of diabetes.
Diabetes is characterized by a relative or absolute lack of insulin that results in hyperglycaemia. Diabetes mellitus 
type 1 (T1DM) is caused by the autoimmune destruction of the pancreatic beta cells whereas Diabetes mellitus 
type 2 (T2DM) is characterized by insulin resistance that is not sufficiently compensated by insulin secretion of 
the pancreatic beta-cells. At diagnosis of T2DM, patients already display metabolic alterations and many of them 
also have developed complications including renal disease, retinopathy, polyneuropathy, and coronary artery dis-
ease (CAD)1–3. The delay or even prevention of these complications require early identification of patients at risk 
for diabetes, ideally before or independently of hyperglycemia. The combination of lifestyle factors, anthropomet-
ric (BMI, waist to hip ratio, blood pressure) and metabolic biomarkers (glucose, glycated hemoglobin (HbA1c), 
triacylglycerol, high density lipoprotein (HDL)) identify individuals at risk of diabetes4. However, the prognostic 
value of these risk factors is limited5. As the consequence, novel biomarkers identifying patients at risk for diabe-
tes are searched by both candidate-driven and screening approaches.
Micro-ribonucleic acids (miRNAs) circulating in blood are accessible for biomarker discovery by screen-
ing approaches6,7. MiRNAs are small non-coding RNAs that modify gene expression at the post-transcriptional 
level. They bind to a complementary site in the 3′ untranslated region of their target mRNAs and inhibit their 
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translation or direct their degradation8,9. Thereby, miRNAs regulate many biological processes such as cellular 
differentiation, proliferation, apoptosis, and metabolic homeostasis10. Some miRNAs are released into the circula-
tion either passively upon cell injury and death or actively for intercellular communication11. In the bloodstream, 
miRNAs are protected from degradation by RNAses because they are packaged into exosomes, microparticles, 
apoptotic bodies, or lipoproteins, or linked to RNA-binding proteins12. Interestingly, the serum concentrations 
of specific miRNAs differ with pathological conditions so that miRNAs are increasingly explored as potential 
biomarkers for many diseases13.
Previous miRNA expression profiling studies aiming at the identification of novel biomarkers for T2DM, were 
performed in whole blood14,15, plasma16–18, serum19,20, or exosomes21 Zhu et al.13 and Villard et al.22 performed 
meta-analyses to identify consistently dysregulated miRNAs. Among 18 miRNA profiling studies Zhu et al.13 
identified seven circulating miRNAs (miR-29a, miR-34a, miR-375, miR-103, miR-107, miR-132, miR-142-3p 
and miR-144) as potential biomarkers of T2DM. In their meta-analysis, Villard et al.22 included eight studies 
that compared pre-diabetic patients vs control subjects and 14 studies that compared diabetic vs BMI-matched 
non-diabetic subjects. They found ten miRNAs altered in blood of patients suffering from T2DM (miR-320a, 
miR-222, miR-29a, miR-27a, miR-375, miR-197, miR-20b, miR-17, miR-652, and miR-142-3p). Only three miR-
NAs (miR-142-3p, miR-29a and miR-375) were hence the common finding of the two meta-analyses. Of note, all 
previous profiling studies, except the prospective Bruneck Study18,23, had cross-sectional or case-control designs 
and hence were unable to investigate the prognostic value of circulating miRNAs towards the development of 
new-onset T2DM. The current study addresses this gap and aims at identifying circulating miRNAs that are asso-
ciated with present or incident diabetes.
Results
Discovery of circulating miRNAs associated with the development of future type 2 diabe-
tes. To discover circulating miRNAs associated with the risk of diabetes, we compared the expression of 372 
miRNAs between sex and age-matched patient groups from the VIVIT cohort: All patients had metabolic syn-
drome at baseline while nine patients developed diabetes during a 6-year observation period (incident diabetes) 
and nine did not (no incident diabetes). Circulating miRNA profiles were recorded in four sera per patient that 
were collected at baseline as well as at the 2-, 4-, and 6-year visits. At baseline, the patient groups did not differ 
significantly with respect to sex, age, BMI, fasting glucose, HbA1c, or presence of metabolic syndrome or cardi-
ovascular disease (Supplemental Table S1). MiRNAs were selected as candidate biomarkers for incident diabetes 
if they were significantly up- or downregulated in sera obtained from at least one visit, and showed a consistent 
up- or downregulation in all follow-up samples. According to these criteria, the serum level of miR-10b was 
lower in patients with incident diabetes compared to subjects without incident diabetes, whereas the concentra-
tions of miR-22*, miR-122, miR-192, miR-193b, miR-194, and miR-215 were higher (Supplemental Fig. S1 and 
Supplemental Table S2). In principle the same result was obtained by an alternative analysis in which we com-
pared the individual time points of patients with incident diabetes with the aggregated value from all non-diabetic 
time points (Supplemental Fig. S2). These associations were reproduced by individual quantitative real-time PCR 
(qRT-PCR) assays for miR-122, miR-192, miR-194 and miR-215 but not for miR-10b and miR-22*. The latter two 
miRNAs as well as miR-193b, whose concentrations were close to the limit of detection, were excluded from the 
subsequent validation studies.
Circulating miR-192, miR-194, and miR-215 are elevated in sera of patients with the presence 
of both type 2 diabetes and type 1 diabetes. In a first cross-sectional validation, serum levels of miR-
122, miR-192, miR-194, and miR-215 were investigated by individual qRT-PCR assays for their association with 
glycemic stages in patients of the VIVIT cohort. Because of the selection criteria, the sex- and age-matched 
43 euclycemic control subjects, 43 patients with impaired fasting glucose (IFG), and 43 patients with manifest 
T2DM significantly differed by the prevalence of metabolic syndrome as well as frequency distributions of BMI, 
fasting glucose, HbA1c, C-peptide and insulin (Supplemental Table S3). Kruskal-Wallis H test revealed signifi-
cantly higher levels of miR-192, miR-194 and miR-215 in sera of patients with manifest T2DM as compared to 
patients with euglycemic controls or IFG (manifest T2DM vs NFG: P = 0.004 for miR-192, P = 0.009 for miR-194, 
P < 0.001 for miR-215; manifest T2DM vs IFG: P = 0.028 for miR-192, P = 0.030 for miR-192, P = 0.022 for miR-
215) (Fig. 1, Supplemental Table S4). The serum concentration of miR-122 did not significantly differ between 
any groups.
We next compared the expression of miR-192, miR-194, and miR-215 in sera of 54 patients with T1DM and 53 
non-diabetic control subjects. The two groups resembled each other by age, gender, and BMI but differed signifi-
cantly by higher eGFR, higher plasma levels of glucose and HDL cholesterol as well as lower plasma levels of total 
and LDL cholesterol as well as triglycerides in T1DM patients. Apart from insulin therapy, the T1DM patients 
were more frequently treated with statins and ACE-inhibitors (Supplemental Table S5). The Mann-Whitney U test 
revealed significantly higher serum levels of miR-192 (P = 0.005), miR-194 (P = 0.020), and miR-215 (P = 0.026) 
in sera of subjects with T1DM compared to subjects with NFG. (Fig. 2, Supplemental Table S6).
Circulating miR-192 and miR-194 predict the development of future type 2 diabetes. The asso-
ciation of candidate miRNAs with incident T2DM was assessed in 213 patients of the VIVIT cohort without 
manifest T2DM at baseline. The miRNA levels were compared between patients who developed T2DM during the 
6-year observation period (n = 35) and those who did not (n = 178). Patients with incident T2DM differed sig-
nificantly from patients without incident T2DM by higher concentrations of fasting glucose, HbA1c, C-peptide, 
triglycerides (Supplemental Table S7) as well as higher levels of miR-192 and miR-194 but not by miR-122 and 
miR-215 levels (Fig. 3, Supplemental Table S8).
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Univariate logistic regression revealed that miR-192 and miR-194, along with fasting glucose, HbA1c and 
C-peptide were significant predictors for the development of T2DM (Table 1). This finding persisted in multivar-
iate logistic regression models, when either the significant variables from the univariate models (fasting glucose, 
HbA1c, C-peptide; Table 2) or classical risk factors (sex, age, metabolic syndrome; Supplemental Table S9) were 
set as covariates. The triple combination of HbA1c (OR 3.08, 95%CI 1.27–7.50; P = 0.013), C-peptide (OR 1.94, 
95%CI 1.18–3.19; P = 0.009) and miR-192 (OR 1.84, 95%CI 1.23–2.75; P = 0.003) performed best and explained 
23.8% (Nagelkerke R2) of the variance (Model 2a in Table 2). Interestingly, adjustment for miR-194 made miR-
192 a non-significant predictor and vice versa, while each regression model kept its statistical significance. This 
was probably due to the strong correlation between these two co-expressed miRNAs (see below)24. MiR-122 and 
miR-215 were not associated with incident T2DM.
The ability of the candidate miRNAs to predict incident T2DM was also evaluated by means of C-statistics and 
compared to the performance of the other significant predictors (glucose, HbA1c, C-peptide) (Fig. 3, Table 3). The 
highest area under the curve (AUC) and hence best predictive values were observed for fasting glucose (0.72, 95% 
CI: 0.62–0.82) and C-peptide (0.72, 95% CI: 0.63–0.81). HbA1c (0.67, 95% CI 0.58–0.77), miR-192 (0.68; 95% CI: 
0.59–0.77) and miR-194 (0.65, 95% CI: 0.56–0.75) showed slightly lower but similar AUCs. In line with the results 
of the logistic regression, the combination of miR-192, HbA1c and C-peptide performed best in predicting T2DM. 
This triple combination increased the AUC compared to fasting glucose or C-peptide alone by 0.07 to 0.79 [95% 
CI: 0.73–0.84] (Fig. 4, Table 3). This increase was statistically significant when compared to the AUC of C-peptide 
(P = 0.012) but not when compared to the AUC of fasting glucose (P = 0.172). MiR-192 contributed 0.05 to this 
increase. Then, optimum cutoffs to maximize sensitivity and specificity were calculated with the Youden Index25 and 
were 2.66 ∆Cq for miR-192 and 2.95 ∆Cq for miR-194. For fasting glucose and HbA1c the upper limit of the normal 
range according to the American Diabetes Association (ADA) was used as the cutoff (glucose: 5.60 mmol/l, HbA1c: 
5.70% [~39 mmol/mol]), because the cutoffs calculated with the Youden index (glucose: 5.52 mmol/l, HbA1c: 5.85% 
[~40 mmol/mol]) were very close. Based on the optimal cutoff, the triple combination of miR-192, HbA1c and 
C-peptide predicted the development of T2DM with a sensitivity of 83% and a specificity of 69%. Moreover, inte-
grated discrimination improvement (IDI), that is a measure of improved risk prediction of a new model compared 
to a reference model26, was significantly different from zero when the triple combination was compared to glucose or 
HbA1c alone (P = 0.015 and P < 0.001). Relative IDI was 106% when glucose was used as the reference model and 
190% when HbA1c was used. No other combination further improved the predictive performance.
Figure 1. Serum levels of miR-122 (a), miR-192 (b), miR-194 (c), and miR-215 (d) in subjects with NFG, 
IFG, and manifest type 2 diabetes. The miRNAs -192, -194 and -215 were significantly higher in patients 
with manifest diabetes as compared to patients with NFG or IFG. Circulating miR-122 did not significantly 
differ between any groups. To compare miRNA levels between patient groups the Kruskal-Wallis test was 
run followed by Dunn’s procedure for pairwise comparisons and a Bonferroni correction for multiple testing. 
T2DM: type 2 diabetes mellitus. Horizontal lines show the medians.
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To further assess the predictive potential of the candidate miRNAs, patients were assigned to either a «high 
risk» or a «low risk» group for future T2DM depending on whether their miRNA levels were below or above the 
optimum cutoff calculated using the Youden Index25. Then, the time to T2DM diagnosis was compared between 
«high risk» and «low risk» patients by means of Kaplan-Meier estimation and log-rank test. «High risk» patients 
with elevated levels of miR-122, miR-192 and/or miR-194 showed significantly different disease-free survival 
distributions compared to «low risk» patients with low circulating miRNAs (χ2(1) = 3.96, P < 0.047 for miR-122; 
χ2(1) = 14.55, P < 0.001 for miR-192; χ2(1) = 10.84, P = 0.001 for miR-194) (Fig. 3, Table 3). However, no sig-
nificant change of survival distributions was found for low versus high miR-215 concentrations (χ2(1) = 0.446, 
P = 0.504; Supplemental Fig. S3).
Figure 2. Serum levels of miR-192 (b), miR-194 (c), and miR-215 (d) in subjects with NFG or type 1 diabetes. 
Serum levels of miRNA -192 were significantly higher in patients with T1DM diabetes as compared to patients 
with NFG. To compare miRNA levels between patient groups the Kruskal-Wallis test was run followed by 
Dunn’s procedure for pairwise comparisons and a Bonferroni correction for multiple testing. T1DM: type 1 
diabetes mellitus. Horizontal lines show the medians.
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Correlation of circulating miRNAs with anthropometric and metabolic measures. A Spearman’s 
rank-order regression analysis (Table 4) revealed medium to strong positive correlations between serum lev-
els of miR-122, miR-192, miR-194, and miR-215 in both the VIVIT and Manchester cohorts. In the VIVIT 
cohort all four miRNAs correlated with the activity of the liver enzymes alanine transaminase (ALT), aspartate 
transaminase (AST) and gamma glutamyl transferase (GGT). In addition, miR-192 and miR-194 correlated with 
C-peptide, insulin, and homeostasis model assessment-index ratio (HOMA-IR). In the VIVIT cohort but not in 
the Manchester cohort, miR-192 and miR-215 correlated with estimated glomerular filtration rate (eGFR) and 
inversely with cystatin C levels.
MiRNAs-192 and -194 in sera of mice with diabetes or metabolic syndrome. Finally, we investigated 
whether serum levels of miR-192 or miR-194 are also altered in two mouse models of T2DM and insulin resist-
ance of different pathogenic origin (Fig. 4)27. Compared to wild type mice, protein kinase B (Akt2)−/− mice27 
showed 25% and 400–1000% higher plasma concentrations of glucose (Fig. 4A) and insulin (Supplementary 
Fig. 4A), respectively, as well as significantly elevated serum levels of both miR-192 or miR-194 (Fig. 4B,C). Upon 
a high fat diet (HFD) but not upon a low fat diet (LFD), mice expressing the mutant apoE3Leiden and CETP 
(E3L*CETP) develop obesity, fatty liver, and insulin resistance27. Glucose and insulin levels were elevated in half 
Figure 3. Associations of circulating miR-192 (a,c) and miR-194 (b,d) with incident diabetes as analyzed by 
C-statistics (a,b) or Kaplan-Meier survival functions (c,d). The ROC curves of the four most accurate predictors 
are presented (a and b). The combination of miR-192 with HbA1c and C-peptide resulted in the highest AUC 
and hence was the best model to predict incident diabetes (a). The sensitivity, specificity, and AUC values for 
the predictors are summarized in Table 3. Kaplan-Meier survival curves show the time to diabetes-diagnosis 
for patients with low versus high serum levels of miR-192 (c) and miR-194 (d). Low risk and high risk refer 
to optimal cutoff points calculated with the Youden-Index (2.66 ∆Cq for miR-192, 2.95 ∆Cq for miR-194). 
iT2DM: incident type 2 diabetes mellitus.
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of the mice (p = 0.054, Fig. 4D, and p = 0.0121, Supplementary Fig. 4B, respectively) However, serum levels of 
miR-192 and miR-194 did not differ between HFD and LFD mice (Fig. 4E,F).
Discussion
By combining a biomarker discovery study with three targeted validation studies, we found elevated serum levels 
of miR-192, miR-194 and miR-215 associated with the presence of both T1DM and T2DM, and miR-192 and 
miR-194 associated with the incidence of T2DM. The association of miR-192 and miR-194 with incident T2DM 
showed similar strength as fasting glucose, HbA1c, and C-peptide. With AUCs ranging between 0.67 and 0.72, 
none of the five individual predictors was good enough to serve as a clinically useful prognostic biomarker per 
se, but the combination of miR-192, HbA1c, and C-peptide nearly reached the threshold of clinical utility26 and 
predicted the disease with an AUC of 0.79 (95%CI [0.73–0.84]) in a period of at least 2–6 years before onset. Of 
note, serum levels of miR-192 and miR-194 were also elevated in Akt2−/− mice28 which have a diabetes-like 
syndrome due to blocked insulin signaling but not in E3L*CETP mice which develop a diabetes-like syndrome 
upon fat-overload27.
The finding of both miR-192 and miR-194 testifies the quality of our unbiased approach because they are 
expressed by the same precursor miRNA (miR-192/–194 pri-miR)24. Five other but smaller and non-prospective 
miRNA profiling studies found associations of miR-192 or miR-194 serum levels with glycemic stage15,16,29–31: 
One study found miR-192 increased in sera of patients with prediabetes but not altered in sera of patients with 
manifest T2DM. Interestingly, the authors also reported that miR-192 decreases to normal levels in both insulin 
resistant humans and mice upon sustained physical exercise normalizing the metabolic phenotype29. A similar 
observation was made upon treatment of pre-diabetic patients with 2000 U vitamin D/day: Circulating levels of 
miR-192 dropped upon treatment with vitamin D but not placebo and the change in miR-192 levels correlated 
with the changes of glucose levels32. Circulating miR-194 seems also to be associated with the changes of glu-
cose levels: A study following metabolic syndrome patients over 1 year showed that miR-194 was differentially 
expressed in patients with variable fasting glucose levels compared to patients with stable glucose levels33. An 
observational study reported increased levels of miR-194 in polycystic ovary syndrome patients with impaired 
glucose metabolism compared to patients with normal glucose metabolism30. Likewise miR-192 levels were found 
Standardized covariates
OR (per increase of 1 SD of 
the biomarker) (95% CI) P-value
Nagelkerke R2 
(%)
Sex 0.66 (0.28–1.53) 0.329 0.8
Age 1.01 (0.70–1.44) 0.979 <0.1
MetS (ATPII) 1.97 (0.91–4.30) 0.087 2.1
Fasting glucose 4.26 (1.74–10.42) 0.002 8.2
HbA1c 3.83 (1.65–8.90) 0.002 8.0
C-peptide 2.16 (1.41–3.32) <0.001 10.7
coronary stenosis > 50% 1.702 (0.79–3.69) 0.177 1.5
History of myocardial infarction 1.336 (0.62–2.89) 0.462 0.4
History of stroke 4.078 (0.87–19.09) 0.074 2.2
miR-122 1.07 (0.74–1.53) 0.732 0.1
miR-192 1.95 (1.34–2.83) <0.001 11.0
miR-194 1.91 (1.29–2.83) 0.001 9.7
miR-215 0.89 (0.60–1.31) 0.557 0.03
Table 1. Risk of incident diabetes according to different univariate logistic regression models.
Standardized 
covariates
OR (per increase of 
1 SD of the biomarker) (95% CI) P-value Nagelkerke R2 (%)
Model 1a
Fasting glucose 2.42 (0.91–6.39) 0.076
21.3C-peptide 1.92 (1.18–3.12) 0.008
miR-192 1.65 (1.11–2.45) 0.014
Model 1b
Fasting glucose 2.88 (1.09–7.63) 0.033
20.4C-peptide 1.84 (1.13–3.00) 0.015
miR-194 1.58 (1.05–2.39) 0.029
Model 2a
HbA1c 3.08 (1.27–7.50) 0.013
23.8C-peptide 1.94 (1.18–3.19) 0.009
miR-192 1.84 (1.23–2.75) 0.003
Model 2b
HbA1c 2.90 (1.21–6.99) 0.017
21.4C-peptide 1.93 (1.18–3.16) 0.009
miR-194 1.65 (1.09–2.52) 0.019
Table 2. Risk of incident diabetes according to different multivariate logistic regression models.
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increased in full blood samples of patients or rats with T2DM as compared to normoglycemic controls15. By con-
trast to those and our studies, Ortega et al.16 and Yang et al.31 reported decreased rather than elevated miR-192 
serum levels in patients with manifest T2DM. Ortega et al.16 also found, that miR-192 concentration increased 
upon treatment with metformin. In agreement with our data, a higher abundance of miR-192, miR-194 and miR-
122 was associated with greater insulin resistance in 2317 non-diabetic subjects of the Framingham Heart Study34. 
Moreover, a meta-analysis of several profiling studies identified miR-192 upregulated in liver of diabetic subjects 
compared to liver of nondiabetic subjects13.
The observational design of our study allows any conclusion on neither the origin of miR-192 and miR-194 
in the circulation nor on the pathogenic relationship between their serum levels with prevalent or incident dia-
betes. Due to the systemic nature of diabetes and its complications, miRNAs may be released from several organs 
in response to cellular stress, injury, or death. MiR-192 and miR-194 are expressed by many organs that either 
play a role in the pathogenesis of T2DM (e.g. beta cells or liver)30,35,36 or are affected by diabetic complications, 
sometimes even before the onset of manifest T2DM (e.g. liver or kidney)30,35,36. Thus, the association of miR-192 
and miR-194 may reflect causality, reverse causality, or an indirect bystander relationship. Supporting cause- or 
effect-relationships with insulin action and glucose utilization, we and others30,34–36 found significant correlations 
of miR-192 and miR-194 levels with the HOMA-IR index. Also, in support of direct relationships miR-192 was 
found among the top ten most abundant miRNAs in pancreatic beta-cells37 indicating a potential relevance of 
this miRNA for beta cell function and survival. This may be reflected by the association of miR-192 and miR194 
with T1DM. In line with this, miR-192 targets the mRNA of the transcription factor Rfx6, which regulates islet 
formation and insulin production38. Serum levels of miR-194, were associated with residual beta cell function in 
children with T1DM39. MiR-192 and miR-194 are also expressed by liver, skeletal muscle and adipocytes where 
they were found to regulate insulin signaling15,30,40,41. MiR-194 regulates the phosphorylation of AKT, glycogen 
synthase kinase 3 (GSK3) as well as oxidative phosphorylation in skeletal muscle cells40. In rats, miR-194 was 
found to promote hyperglycemia by suppressing IGF-1 receptor expression and the phosphoinositide-3-kinase 
(PI3K)/AKT signal pathway in skeletal muscle41. This interaction of Akt with miR-192 and miR-194 may be 
reflected by the elevated serum levels of miR-192 and miR-194 in sera of Akt2−/− mice.
Three recent studies revealed elevated miR-192 in liver tissue and serum of patients with non-alcoholic fatty 
liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)42–44, which are both risk factors of incident 
T2DM and comorbidities of prevalent T2DM. In our cohort, serum levels of miR-192, miR-194, and miR-215 
correlated with the serum activities of liver function parameters AST, ALT, and GGT as well as serum levels of 
triglycerides. However, feeding of E3L*CETP mice with HFD which induces an NAFLD-like phenotype with 
insulin-resistance, hyperglycemia, hyperlipidemia and hepatic steatosis27 did not lead to any changes in serum 
levels of miR-192 or miR-194. This contradiction may reflect that NAFLD can be both the cause and conse-
quence of insulin resistance45. On the one hand hyperinsulinemia compensating for insulin resistance promotes 
lipogenesis in the liver by both Akt2-dependent and Akt2-independent signaling events. On the other hand, the 
C-statistics Sensitivity and Specificity IDI (integrated discrimination improvement)
AUC (95% CI) P-value Sensitivity Specificity
Specificity at 80% 
sensitivity absolute IDI (95% CI) P-value relative IDI
Individual parameters
Fasting glucose 0.72 (0.62–0.82) <0.001 60% 74% 57%
HbA1c 0.67 (0.58–0.77) 0.001 69% 51% 39%
C-peptide 0.72 (0.63–0.81) <0.001 77% 63% 60%
miR-192 0.68 (0.59–0.77) 0.001 94% 40% 48%
miR-194 0.65 (0.56–0.75) 0.004 66% 64% 40%
Combined parameters
Fasting glucose 0.72 (0.62–0.82) <0.001 60% 74% 57% reference
Glucose, C-peptide 0.76 (0.70–0.81) <0.001 89% 55% 57% 0.039 (0.000–0.039) 0.050 50%
Glucose, miR-192 0.74 (0.64–0.84) <0.001 66% 82% 51% 0.047 (0.006–0.053) 0.026 60%
Glucose, miR-194 0.76 (0.66–0.85) <0.001 54% 91% 55% 0.045 (0.007–0.051) 0.021 58%
Glucose, C-peptide, miR-192 0.77 (0.71–0.83) <0.001 77% 70% 61% 0.080 (0.024–0.104) 0.005 103%
Glucose, C-peptide, miR-194 0.78 (0.72–0.83) <0.001 63% 84% 64% 0.070 (0.022–0.092) 0.005 91%
HbA1c 0.67 (0.58–0.77) 0.001 69% 51% 39% reference
HbA1c, C-peptide 0.75 (0.69–0.81) <0.001 77% 67% 63% 0.050 (0.011–0.061) 0.011 90%
HbA1c, miR-192 0.75 (0.67–0.84) <0.001 74% 70% 48% 0.072 (0.022–0.095) 0.005 131%
HbA1c, miR-194 0.73 (0.65–0.82) <0.001 86% 51% 53% 0.059 (0.014–0.073) 0.010 107%
HbA1c, C-peptide, miR-192 0.79 (0.73–0.84) <0.001 83% 69% 71% 0.105 (0.043–0.148) <0.001 190%
HbA1c, C-peptide, miR-194 0.78 (0.72–0.83) <0.001 89% 61% 69% 0.087 (0.035–0.122) 0.001 158%
Table 3. Prognostic performance of circulating miRNAs and established biomarkers towards incident diabetes. 
AUC with 95% CI, sensitivity, specificity, and IDI (integrated discrimination improvement) are presented in 
table. IDI is a measure of improved risk prediction of a new model compared to a reference model. Sensitivity 
and specificity were calculated based on optimum cutoffs calculated with the Youden Index25.
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intracellular increase of lipids promote pro-inflammatory signaling cascades such as NF-KB, JNK, and SOCS as 
well as activation of the inflammasome which inhibit the insulin-receptor signaling towards gluconeogenesis 
and glycogen synthesis45. The discrepant findings of elevated miR-192 and miR194 in akt2−/− mice but no 
alteration in HFD fed E3L*CETP mice may hence reflect the different pathogenesis of hyperglycemia in these 
mice: The lack of Akt2 causes insulin resistance however without promoting lipogenesis, steatosis and dyslipi-
demia, because some lipogenic effects of insulin involve signaling via Akt246. In apoE3L*CETP mice steatosis is 
promoting insulin resistance46. In fact, functional studies point to the involvement of miR-192 or miR-194 in the 
pathogenesis of NASH. MiR-192 was found induced by docosahexaenoic acid in hepatocytes where it modulates 
lipid metabolism by targeting caveolins, fatty acid elongases, and the VLDL receptor36. Overexpressing or inhib-
iting miR-192 in the liver resulted in changes of total triacylglycerol accumulation36. MiR-194 inhibits the inflam-
matory toll-like receptor 4 pathway by targeting tumor necrosis factor receptor-associated factor 6 (TRAF6)47 
and prevents stellate cell activation by targeting rac 148. MiR-192 is known to be upregulated by TGF-β149, a key 
fibrogenic cytokine in hepatic stellate cells.
As bystanders rather than cause or effect of diabetes, elevated miR-192 and miR-194 levels may be caused by 
co-morbidities of diabetes and prediabetes. Notably nephropathy50,51 has been repeatedly associated with altered 
miR-192 serum levels, which in the VIVIT cohort correlated with two biomarkers of kidney function, namely 
eGFR and cystatin C (Table 4). Of note we did not observe this association in the probands of the Manchester 
cohort who were younger and had normal kidney function. In the kidney, miR-192 is regulated by TGF-β1 upon 
high blood glucose levels. Moreover, miR-192 was found to play important roles in renal fibrosis, a key fea-
ture in diabetic nephropathy52–57. However, controversial data were reported on the association of miR-192 with 
nephropathy34. Chien et al.50 found higher miR-192 levels in patients with overt proteinuria group compared to 
those with microalbuminuria. In contrast, Ma et al.51 found lower levels of miR-192 in patients with macroalbu-
minuria compared to those with microalbuminuria or normoalbuminuria. These contradictory results may be 
due to differential expression of miR-192 that depend on the stage of renal injury and/or the cell type-specific 
response of miR-192 to TGF-β134. In line with this hypothesis, miR-192 was increased in mouse mesangial cells 
treated with TGF-β1 and in renal glomeruli from mouse models of diabetes depicting early stages of diabetic 
nephropathy (streptozotocin-injected type-1 diabetic mice and type-2 diabetic db/db mice) compared to nondi-
abetic control mice49,55,57. Conversely, miR-192, is downregulated in models of more severe or late-stage diabetic 
nephropathy in diabetic ApoE-deficient mice54 and in biopsies from patients in late stages of diabetic nephrop-
athy58. MiR-192 was also reported in some studies of cultured proximal tubular epithelial cells treated with high 
glucose or TGF-β1, which was associated with increased fibrosis54,58. Tubular damage and necrosis/apoptosis 
are usually observed in the later stages of diabetic nephropathy, which could lead to decreases in miRNA levels.
Figure 4. Serum levels of glucose, miR-192 and miR-194 in mouse models of diabetes. Glucose concentrations 
were higher in Akt knockout mice compared to wild type mice (a) and in apoE3Leiden*CETP transgenic mice 
fed with a high fat diet versus low fat diet (d). Circulating miR-192 (b,c) and miR-194 (e,f) were elevated in Akt2 
knockout mice compared to wild type mice but not in apoE3Leiden*CETP transgenic mice fed with a high fat 
diet versus low fat diet. To compare miRNA levels between groups of mice the Student’s t-test was performed. 
C57BL/6: wild type mice; Akt2−/−: Akt2 knockout mice; apoE3L*CETP: apoE3Leiden*CETP transgenic mice; 
LFD: low fat diet; HFD: high fat diet.
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Our study has strengths and limitations. One strength is the combination of comprehensive miRNA profiling 
in a discovery study with validation by both cross-sectional and longitudinal cohort studies as well as animal 
models. Only three other studies reported on the associations of circulating miRNAs with incident T2DM18,23,59,60, 
while the vast majority of the studies only used cross-sectional validation. Of those investigating incident T2DM, 
the Bruneck study found lower levels of miR-15a, miR-29b, miR-126, and miR-223, as well as elevated levels of 
miR-28–3p and miR-122 to be associated with incident T2DM18,23. Flowers et al.59 found six miRNAs to be asso-
ciated with incident T2DM in an Asian Indian population: miR-122, miR-15a, miR-197, miR-320a, miR-423, and 
miR-486. De Candia et al.60 investigated a small group of patients with IFG that progressed to T2DM (n = 4) or 
not (n = 5) and identified miR-143-3p, miR-320b and miR-320c to be differentially expressed. Thus, only miR-15a 
and miR-122 have been repeatedly been associated with incident T2DM. Importantly, we also identified miR-122 
as a potential biomarker of incident T2DM in our discovery study. In our validation studies, elevated miR-122 
levels were significantly associated with a shorter time to T2DM diagnosis when using Kaplan-Meier estimation 
(Supplemental Figure S3), but there was neither any association with glycemic states nor with incident T2DM 
when logistic regression analysis was applied. Of note, miR-192 was not included in the studies of Flowers et al.59  
and Candia et al.60 while miR-194 was not included in any of the three studies investigating incident T2DM. 
Another strength of the present study is the biannual recall of probands for extensive examination including 
oral glucose tolerance testing (oGTT) that makes the rule-in and rule-out of incident T2DM more accurate than 
follow-up by phone call interviews or registries.
One limitation is the investigation of patients who had either suspected or established CAD and were there-
fore at higher risk to develop T2DM than individuals from the general population. However, neither in the dis-
covery study (Supplemental Table S1) nor in the validation studies (Supplemental Tables S3 and S7), the patient 
groups differed significantly by prevalence of acute myocardial infarction (AMI) or stroke as well as the presence 
of significant coronary stenosis. In previous studies serum levels of miR-192 were associated with myocardial 
fibrosis61 as well as the development of ischemic heart failure in AMI patients62. This limitation, and - compared 
to biomarker studies beyond the miRNA research field - the relatively small patient groups analyzed in this work, 
calls for further validation in a larger and population-based prospective cohort study. We can neither exclude 
that our initial miRNA profiling study overlooked miRNAs that are potential biomarkers of diabetes and thereby 
escaped our validation studies. Thus, we identified only one of the miRNAs previoiusly associated with inci-
dent T2DM, namely miR-12218. In this respect it is noteworthy to emphasize the different samples and methods 
used by us and Willeit and colleagues23, namely exclusively serum versus plasma and serum, Exiqon versus Life 
Technologies, normalization to endogenous reference miRNAs versus artificial spike-in RNAs. In this respect it is 
patient 
number miR-122 miR-192 miR-194 miR-215
Age 213 −0.301 *** −0.248 *** −0.231 ** −0.262 ***
BMI 213 0.125 0.128 0.095 0.087
Glucose homeostasis
Fasting glucose 213 0.075 0.142 * 0.081 −0.028
HbA1 213 −0.054 0.034 0.017 −0.060
C-Peptide 213 0.232 ** 0.237 *** 0.280 *** 0.026
Insulin 194 0.121 0.164 * 0.165 * 0.038
HOMA-beta 194 0.112 0.074 0.146 * 0.042
HOMA-IR 194 0.129 0.183 * 0.170 * 0.042
Kidney function
Creatinine 207 −0.034 −0.103 0.012 −0.176 *
Cystatine C 207 −0.080 −0.232 ** −0.071 −0.205 **
eGFR (CKD-EPI) 207 0.189 ** 0.217 ** 0.132 0.292 ***
Liver values
AST 191 0.325 *** 0.231 ** 0.267 *** 0.229 **
ALT 191 0.357 *** 0.297 *** 0.154 * 0.396 ***
GGT 191 0.390 *** 0.307 *** 0.271 *** 0.218 **
Lipid values
Triacylglycerol 123 0.356 *** 0.215 * 0.273 ** 0.080
Cholesterol 123 0.026 −0.031 0.055 0.067
HDL 123 −0.187 * −0.069 −0.094 0.045
LDL 123 −0.011 −0.169 −0.110 −0.010
miRNAs
miR-122 213 0.565 *** 0.591 *** 0.434 ***
miR-192 213 0.705 *** 0.450 ***
miR-194 213 0.317 ***
Table 4. Spearman correlation between circulating miRNAs, anthropometric and laboratory parameters (at 
study baseline). CKD-EPI: Chronic-Kidney-Disease-Epidemiology, *P < 0.05; **P < 0.01; ***P < 0.001.
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worth mentioning that one of the reference miRNAs recommended by Exiqon, miR-103, has been associated with 
T2DM22 and NAFLD63. However, in our population, miR-103 was not associated with present or incident T2DM. 
Moreover, exclusion of miR-103 as a reference miRNA and hence normalization for miR-106a and miR-425 only 
did not change the results (not shown).
Neither did we identify any of the seventeen miRNAs that according to two recent meta-analysis of profiling 
studies on blood samples (i.e. plasma, serum, peripheral blood mononuclear cells, or whole blood) are associ-
ated with prevalent T2DM13. Among them, in the discovery study we observed a significant association of the 
most frequently T2DM-associated miRNA - miR-29a - with incident T2DM in the 2-year follow-up samples 
(P = 0.014) but not beyond. Because miR-29a did not fulfill one of our pre-defined inclusion criteria – consistent 
deregulation during the follow-up – we excluded it from the validation studies. Our discovery study may also have 
overlooked some of the seventeen miRNAs previously associated with present T2DM because we searched for 
miRNAs associated with incident T2DM rather than present T2DM. Circulating miRNAs may remain unchanged 
in patients with incident T2DM but alter only after onset of the disease.
In conclusion, we identified and validated increased serum levels of miR-192 and miR-194 as biomarkers of 
both prevalent and incident T2DM in the VIVIT cohort. The independence of their association from established 
risk factors and their ability to improve risk prediction in combination with established risk factors may make 
them useful for improving risk stratification of pre-diabetic patients. In this regard, the associations of serum and 
tissue miR-192 or miR-194 with NASH and diabetic nephropathy make them interesting for early control not 
only of euglycemia but also the prevention of diabetic complications. However, further studies are needed to test 
whether the results observed in the VIVIT cohort are replicated in other populations.
Methods
Study design. Circulating miRNAs were investigated in a clinical discovery study and three clinical validation 
studies and two mouse models of diabetes. For the initial discovery study as well as two clinical validation studies, 
256 patients were selected from the larger VIVIT cohort61 based on the availability of fasting and non-hemolytic 
sera stored at −80 °C as well as enrollment and follow-up data for incident T2DM. In the discovery step we applied 
PCR-based arrays covering 372 miRNAs (Exiqon, Vedbaek, Denmark) to sera that were collected at baseline 
as well as at the 2-, 4- and 6-year follow-up visits from nine metabolic syndrome patients with incident T2DM 
and nine sex- and age-matched metabolic syndrome patients without incident T2DM (Supplemental Table S1). 
Candidate miRNAs were validated by using qRT-PCR. In the first cross-sectional validation study we examined 
the association of the candidate miRNAs with glycemic stages in sex- and age-matched patient groups: 43 patients 
with NFG, 43 patients with IFG, and 43 patients with manifest T2DM (Supplemental Table S3). In the longitudi-
nal validation study we investigated the association of the candidate miRNAs with incident T2DM in 213 patients. 
Of these patients, 35 individuals developed T2DM during the 6-year observation period and 178 individuals did 
not (Supplemental Table S7).
In the Manchester follow-up study, levels of miR-192, miR-194 and miR-215 in sera from 59 patients with 
T1DM and 54 probands with NFG were evaluated using qRT-PCR.
Finally, the candidate miRNAs were compared between Akt2 knockout mice and wild type mice, as well as 
between the apoE3Leiden*CETP transgenic mice fed with a high fat diet versus low fat diet.
VIVIT cohort. Patients were selected from a prospective cohort study enrolled by the Vorarlberg Institute 
for Vascular Investigation and Treatment (VIVIT; Feldkirch, Austria)64 between September 1999 and October 
2000 while they underwent coronary angiography for the evaluation of either suspected or established stable 
CAD. Clinical and laboratory examinations were performed at enrollment and every two years thereafter during 
an 8-year follow-up period. The study was approved by the Ethics Committee of the University of Innsbruck 
(Austria) and was performed in accordance with relevant guidelines and regulations. All participants gave written 
informed consent.
T2DM was diagnosed by either a physician at VIVIT or a referring physician based on oGTT according to the 
ADA criteria65. Individuals were classified to have incident T2DM, if they had no T2DM at the baseline visit of the 
present investigation (which corresponds to the 2-year visit of the VIVIT study cohort published previously64), 
but developed T2DM at any time during subsequent six years of observation. Metabolic syndrome was diagnosed 
according to National Cholesterol Education Program-Adult Treatment Panel III (NCEP ATP III) criteria66. NFG 
was defined as fasting glucose levels <5.6 mmol/L (100 mg/dL) at all follow-up visits. IFG was defined as glucose 
levels between 5.6 and 6.9 mmol/L (100–125 mg/dL) at least at two follow-up visits.
Manchester cohort. Recruitment of patients and collection of blood samples were conducted in hospitals of 
the Central Manchester University Hospitals NHS Foundation Trust. Patients between 18 and 75 years of age were 
enrolled. T1DM patients and euglycemic control subjects with a history or clinical and/or ECG evidence of CHD 
were excluded. The study was approved by the NRES Committee North West – Greater Manchester Central and was 
performed in accordance with relevant guidelines and regulations. All participants gave written informed consent.
Animals. All experimental protocols were in accordance with institutional guidelines and were approved by 
the Greek Federal Veterinary Office. Akt2 knockout mice (Akt2−/−)28 and C57BL6/J wild type littermates were 
obtained from Dr Christos Tsatsanis (University of Crete Medical School). ApoE3Leiden and hCETP transgenic 
mice (E3L*CETP)27 mice were obtained from TNO Leiden. All mice were maintained at the animal facility of 
the Institute of Molecular Biology and Biotechnology of Heraklion Greece under pathogen free conditions on a 
12 h light/dark cycle. Akt2−/− mice and their control littermates (n = 7 in each group) were fed standard rodent 
chow and sacrified at the age of 12 weeks. Starting at the age of 12 weeks male E3L*CETP mice were fed for 12 
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weeks with either a low fat diet containing 20% protein, 70% carbohydrate and 10% fat (LFD, n = 4) or a high 
fat diet containing 20% protein, 20% carbohydrate, 60% fat and 0,25% cholesterol (HFD, n = 6) before they were 
sacrificed. The mice were anesthetized with isoflurane and their blood was collected by cardiac puncture.
Measurement of miRNAs in human serum. Total RNA was isolated from 200 µl serum using 
column-based systems (discovery sample: miRNeasy Mini Kit, Qiagen, Hilden, Germany; validation samples: 
miRCURY RNA Isolation Kit-Biofluids, Exiqon) according to the manufacturers’ protocols with minor modi-
fications (see Supplemental Methods).The RNA was either immediately reverse transcribed or stored at −80 °C.
For the discovery study, 4 µL RNA solutions were reverse transcribed using the miRCURY LNA Universal RT 
cDNA synthesis kit (Exiqon). Samples were screened for the expression of 372 miRNAs by qRT-PCR based arrays 
(Human panel I V2.M, miRCURY LNA SYBR Green Master Mix; Exiqon) on a 7900HT Fast qRT-PCR System 
(Applied Biosystems, Foster City, California, USA). The amplification curves were examined with the SDS 2.4 
software (Applied Biosystems). Normalized values (∆Cq) were obtained as the raw Cq value minus the arithme-
tic average of raw Cqs for all miRNAs with reliable results (Cq values < 37).
For the validation studies, 2 µL RNA solutions were reverse transcribed using the miRCURY LNA Universal 
RT cDNA synthesis kit (Exiqon). MiRNAs were measured using the ExiLENT SYBR Green Master Mix according 
to the manufacturer’s instructions. PCR assays were performed in triplicates on a LightCycler 480 II qRT-PCR 
System (Roche, Rotkreuz, Switzerland) and all miRNAs were detected at Cq < 37. The amplification curves were 
analyzed using the Light Cycler software version 1.5 (Roche). Normalized values (∆Cq) were obtained as the raw 
Cq value minus the arithmetic average of raw Cqs for the three reference miRNAs miR-103, miR-106a and miR-
425. See Supplemental Methods for more details on normalization.
Measurement of miRNAs in murine serum. The mice were anesthetized with isoflurane and their blood 
was collected by cardiac puncture. After 30 minutes at room temperature, blood samples were centrifuged twice 
at 3,000 rpms/4oC for 20 min each and the serum was used immediately or stored at −80 °C.
Isolation of total microRNAs from mice sera was performed using the miRCURY RNA Isolation Kit (Exiqon) 
according to manufacturer’s protocol. The analyzed serum volume was 50 µl for each mouse. Spike-in template 
(provided by the kit) was added (1 µL) in each serum sample and was used as reference. Isolated miRNA con-
centrations were measured in a TECAN Infinite 200® PRO instrument. Total miRNAs (20 ng) were subjected to 
cDNA synthesis by using the Universal cDNA Synthesis Kit II (Exiqon) as suggested by the manufacturer. The 
cDNAs were used for Real Time PCR analysis using the ExiLENT SYBR® Green master mix and the correspond-
ing primer sets for each miRNA (Exicon) in an Applied Biosystems Step One Plus Real Time PCR system.
Clinical chemistry. For the human studies, hemolysis indices as well as activities of AST, ALT, and GGT were 
determined by photometric tests on a cobas 8000 c701 modular analyzer (Roche). Serum insulin and C-peptide 
were determined by a chemiluminescence enzyme immunoassay on a LIAISON Analyzer (DiaSorin, Saluggia, 
Italy). Cystatine C was determined on a ProSpec nephelometer (Dade Behring, Switzerland). All other clinical 
chemistry parameters were measured in fresh samples as reported previously64.
Glucose in mouse blood was measured by using a GDH-based glucose measurement device (TRUEresult, 
Nipro-Medical Europe, Belgium). Serum insulin levels in mice were determined using enzymatic immunoassay 
(Mercodia Mouse Insulin ELISA, 10-1247-01.
Statistical analysis. Differences in sample characteristics were tested using Chi-square tests for categorical var-
iables and either the Mann-Whitney U Test or the Kruskal-Wallis Test for continuous variables. To compare miRNA 
levels between patient groups the Kruskal-Wallis test was run followed by Dunn’s procedure for pairwise comparisons 
and a Bonferroni correction for multiple testing. Correlations between variables were calculated using Spearman’s 
Rank correlation test. Prospective analysis for future T2DM was performed using binary logistic regression. For this, 
continuous variables were log transformed if necessary and standardized to have the same mean and SD. ORs of the 
miRNAs were calculated with −∆Ct values, because ∆Ct values have an inverse correlation to increasing miRNA 
concentrations. Receiver operating characteristic curve analyses were used to determine the AUCs for established 
biomarkers, miRNAs and combinations thereof67. The optimum cutoff points of the AUCs to discriminate between 
„incident T2DM “ and „no incident T2DM “ were calculated by means of the Youden index25. Kaplan-Meier survival 
analysis followed by a log rank test was conducted to investigate any association of miRNA levels with the time to 
T2DM diagnosis. To compare miRNA levels between groups of mice the Student’s t-test was performed.
Statistical analyses were performed with SPSS (Version 23; IBM, Zürich, Switzerland) and graphs were created 
with Prism7 (GraphPad Software, La Jolla, California). All tests were 2-sided and a P-value < 0.05 was considered 
statistically significant.
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